{"id":"omeprazole-sodium-bicarbonate","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"2-5","effect":"Abdominal pain"},{"rate":"1-3","effect":"Vomiting"},{"rate":"2-4","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL1353","moleculeType":"Small molecule","molecularWeight":"84.01"},"_dailymed":{"setId":"cf6d293e-d70d-443e-8292-d693e93aab55","title":"OMEPRAZOLE/SODIUM BICARBONATE (OMEPRAZOLE) POWDER, FOR SUSPENSION [STRIDES PHARMA SCIENCE LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omeprazole is a proton pump inhibitor (PPI) that irreversibly binds to H+/K+-ATPase in the gastric mucosa, suppressing both basal and stimulated acid secretion. Sodium bicarbonate acts as a buffer to neutralize existing gastric acid immediately upon administration, providing rapid symptom relief while omeprazole's longer-acting mechanism takes effect over several days.","oneSentence":"Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:17.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Acid-related dyspepsia"}]},"trialDetails":[{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT01471925","phase":"PHASE3","title":"Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"","conditions":"Gastroesophageal Reflux Disease","enrollment":""},{"nctId":"NCT00978016","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-09","conditions":"Gastroesophageal Reflux Disease","enrollment":460},{"nctId":"NCT00045799","phase":"PHASE3","title":"Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-05","conditions":"Upper Gastrointestinal Bleeding","enrollment":354},{"nctId":"NCT03100838","phase":"PHASE1","title":"Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-03-20","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT02922933","phase":"PHASE1","title":"A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2016-10-25","conditions":"Volunteers, Healthy Volunteers, Human Volunteers","enrollment":66},{"nctId":"NCT03491995","phase":"PHASE3","title":"A Unique Regimen for Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-04-01","conditions":"Helicobacter Infections","enrollment":600},{"nctId":"NCT01661101","phase":"PHASE3","title":"Management of Myocardial Injury After Noncardiac Surgery Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2013-01","conditions":"Myocardial Injury After Noncardiac Surgery (MINS)","enrollment":1754},{"nctId":"NCT01129778","phase":"NA","title":"Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus","status":"TERMINATED","sponsor":"Stanford University","startDate":"2009-11","conditions":"Barrett Esophagus, Gastroesophageal Reflux","enrollment":27},{"nctId":"NCT00557349","phase":"PHASE4","title":"Ulcer Prevention Study in Post Gastric Bypass Patients","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2006-11","conditions":"Marginal Ulcers","enrollment":40},{"nctId":"NCT02710994","phase":"PHASE1","title":"Pharmacodynamics and Safety of CDFR0209","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2014-05","conditions":"Stomach Ulcer, Gastroesophageal Reflux","enrollment":30},{"nctId":"NCT00808769","phase":"PHASE4","title":"Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2008-11","conditions":"Normal Healthy Subject Population","enrollment":30},{"nctId":"NCT00765206","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT01005719","phase":"PHASE3","title":"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-09","conditions":"Human Experimentation","enrollment":63},{"nctId":"NCT00674115","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT01587885","phase":"PHASE4","title":"Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-01","conditions":"Heartburn","enrollment":48},{"nctId":"NCT01077076","phase":"PHASE3","title":"Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Intragastric Acidity","enrollment":30},{"nctId":"NCT01337804","phase":"PHASE1","title":"A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01","conditions":"Heartburn","enrollment":50},{"nctId":"NCT01493089","phase":"PHASE3","title":"Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Norgine","startDate":"2011-04","conditions":"Gastroesophageal Reflux","enrollment":239},{"nctId":"NCT01710995","phase":"PHASE1","title":"A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Norgine","startDate":"2010-10","conditions":"Acid Reflux, Gastro Oesophageal Reflux Disease","enrollment":20},{"nctId":"NCT00693225","phase":"PHASE4","title":"Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study","status":"COMPLETED","sponsor":"Yvonne Romero","startDate":"2008-01","conditions":"Erosive Esophagitis","enrollment":91}],"_emaApprovals":[],"_faersSignals":[{"count":40,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":29,"reaction":"FATIGUE"},{"count":25,"reaction":"NAUSEA"},{"count":24,"reaction":"DRUG INEFFECTIVE"},{"count":24,"reaction":"RENAL FAILURE"},{"count":21,"reaction":"DIARRHOEA"},{"count":18,"reaction":"HEADACHE"},{"count":17,"reaction":"ACUTE KIDNEY INJURY"},{"count":17,"reaction":"DEATH"},{"count":17,"reaction":"PAIN"}],"_approvalHistory":[{"date":"20200430","type":"ORIG","sponsor":"ANDA REPOSITORY","applicationNumber":"ANDA212587"},{"date":"20200224","type":"SUPPL","sponsor":"SCIEGEN PHARMS","applicationNumber":"ANDA207476"},{"date":"20240111","type":"SUPPL","sponsor":"SCIEGEN PHARMS","applicationNumber":"ANDA207476"},{"date":"20200224","type":"SUPPL","sponsor":"SCIEGEN PHARMS","applicationNumber":"ANDA207476"},{"date":"20240111","type":"SUPPL","sponsor":"SCIEGEN PHARMS","applicationNumber":"ANDA207476"},{"date":"20161206","type":"ORIG","sponsor":"SCIEGEN PHARMS","applicationNumber":"ANDA207476"},{"date":"20200805","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA079182"},{"date":"20231227","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA079182"},{"date":"20150409","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA079182"},{"date":"20231227","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA079182"},{"date":"20130419","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA079182"}],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zegerid","Zegerid Powder for Oral Suspension"],"phase":"marketed","status":"active","brandName":"omeprazole/sodium bicarbonate","genericName":"omeprazole/sodium bicarbonate","companyName":"Food and Drug Administration (FDA)","companyId":"food-and-drug-administration-fda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}